

**Interim Financial Statements**  
**Half Year Ended**  
**June 30, 2013**



**BEXIMCO PHARMACEUTICALS LTD.**

**Beximco Pharmaceuticals Limited**  
**Statement of the Managing Director**

*Dear Shareholders,*

We are pleased to present the un-audited interim financial results for the half year ended June 30, 2013 in compliance with Rule 13 of the Securities and Exchange Commission Rules 1987.

We continued to make progress in the first half of 2013 with reported results largely in line with our expectations. Despite the unstable political environment prevailing in the country throughout this half, we managed to achieve a sales growth higher than the industry average. The Company achieved net sales revenue of Tk. 4,966.4 million, up 14.3% over the corresponding period in 2012. This furnished pre-tax profits of Tk. 955.6 million compared to Tk. 847.7 million earned during the same period in the previous year.

Our export sales registered an excellent 70.7% growth to reach Tk. 331.4 million. In the first quarter of this year, we entered into the European market through commencement of export to Germany and Austria. This is a significant milestone, not only for the Company alone, but for the entire Bangladesh Pharmaceutical Industry. This is for the first time that a Bangladeshi company has succeeded in exporting its own pharmaceutical formulations to Europe. Additionally, in this half, we have obtained marketing authorization for a product in Australia.

We continued to make progress in our domestic markets with the launch of eighteen new products; five of them being introduced in the country for the first time. We have also successfully registered 23 products in seven overseas markets during this six-month period.

At this halfway point in the year, we are pleased with our progress achieved to date and notwithstanding a further worsening of the overall political environment, we remain hopeful of achieving our year-end targets.

We look forward to your continued support.

*Nazmul Hassan*

**Nazmul Hassan**  
Managing Director

**Beximco Pharmaceuticals Limited**  
**Statement of Financial Position (Un-audited)**  
**As at June 30, 2013**

Taka'000

<b>ASSETS</b>	<b>Notes</b>	<b>As at June 30, 2013</b>	<b>As at December 31, 2012</b>
<b>Non-Current Assets</b>		<b>16,331,183</b>	<b>16,392,388</b>
Property, Plant and Equipment- Carrying Value	3	16,126,145	16,201,858
Intangible Assets		201,587	187,079
Investment		3,451	3,451
<b>Current Assets</b>		<b>8,629,567</b>	<b>8,197,422</b>
Inventories	4	2,567,022	2,433,988
Spares & Supplies		413,166	396,176
Accounts Receivable		1,210,546	1,162,405
Loans, Advances and Deposits	5	1,042,813	965,276
Short Term Investment		2,797,418	2,686,598
Cash and Cash Equivalents	6	598,602	552,979
<b>TOTAL ASSETS</b>		<b>24,960,750</b>	<b>24,589,810</b>
<b>EQUITY AND LIABILITIES</b>			
<b>Shareholders' Equity</b>		<b>19,025,445</b>	<b>18,408,162</b>
Issued Share Capital		3,503,349	3,046,390
Share Premium		5,269,475	5,269,475
Excess of Issue Price over Face Value of GDRs		1,689,637	1,689,637
Capital Reserve on Merger		294,951	294,951
Revaluation Surplus		1,356,189	1,406,528
Retained Earnings		6,911,844	6,701,181
<b>Non-Current Liabilities</b>		<b>3,204,839</b>	<b>3,116,704</b>
Long Term Borrowings-Net off Current Maturity (Secured)	7 A	1,284,162	1,469,622
Liability for Gratuity & WPPF		638,401	499,623
Deferred Tax Liability		1,282,276	1,147,459
<b>Current Liabilities and Provisions</b>		<b>2,730,466</b>	<b>3,064,944</b>
Short Term Borrowings		1,166,804	1,526,450
Long Term Borrowings-Current Maturity	7 B	767,009	664,713
Creditors and Other Payables		374,719	470,097
Accrued Expenses		59,170	128,599
Dividend Payable		999	1,021
Income Tax Payable		361,765	274,064
<b>TOTAL EQUITY AND LIABILITIES</b>		<b>24,960,750</b>	<b>24,589,810</b>

*Nazmul Hassan*

**Nazmul Hassan**  
Managing Director

*Ali Nawaz*

**Ali Nawaz**  
Chief Financial Officer

**Beximco Pharmaceuticals Limited**  
**Statement of Comprehensive Income (Un-audited)**  
**For the Half Year Ended June 30, 2013**

Taka'000

	Notes	Half-Year ended June 30, 2013	Half-Year ended June 30, 2012	2nd Quarter (April - June) 2013	2nd Quarter (April - June) 2012
<b>Net Sales Revenue</b>		<b>4,966,358</b>	<b>4,346,354</b>	<b>2,703,345</b>	<b>2,123,984</b>
Cost of Goods Sold	8	(2,728,766)	(2,367,543)	(1,464,384)	(1,151,431)
<b>Gross Profit</b>		<b>2,237,592</b>	<b>1,978,811</b>	<b>1,238,961</b>	<b>972,553</b>
<b>Operating Expenses :</b>		<b>(1,189,495)</b>	<b>(966,300)</b>	<b>(619,698)</b>	<b>(473,270)</b>
Administrative Expenses	9	(196,164)	(150,882)	(104,614)	(77,265)
Selling, Marketing and Distribution Expenses	10	(993,331)	(815,418)	(515,084)	(396,005)
<b>Profit from Operations</b>		<b>1,048,097</b>	<b>1,012,511</b>	<b>619,263</b>	<b>499,283</b>
Other Income		247,518	207,323	125,075	104,804
Finance Cost		(292,218)	(329,725)	(143,573)	(169,469)
<b>Profit Before Contribution to WPP &amp; Welfare Funds</b>		<b>1,003,397</b>	<b>890,109</b>	<b>600,765</b>	<b>434,618</b>
Contribution to WPP & Welfare Funds		(47,781)	(42,386)	(28,608)	(20,696)
<b>Profit Before Tax</b>		<b>955,616</b>	<b>847,723</b>	<b>572,157</b>	<b>413,922</b>
Income Tax Expenses		(297,112)	(234,318)	(196,580)	(107,829)
<b>Profit After Tax</b>		<b>658,504</b>	<b>613,405</b>	<b>375,577</b>	<b>306,093</b>
Other Comprehensive Income		-	-	-	-
<b>Total Comprehensive Income</b>		<b>658,504</b>	<b>613,405</b>	<b>375,577</b>	<b>306,093</b>
Earnings Per Share (EPS) / Restated EPS	Tk.	1.88	1.75	1.07	0.87
Number of Shares used to compute EPS (Note 11)		350,334,907	350,334,907	350,334,907	350,334,907

*Nazmul Hassan*

**Nazmul Hassan**  
Managing Director

*Ali Nawaz*

**Ali Nawaz**  
Chief Financial Officer

**Beximco Pharmaceuticals Limited**  
**Statement of Changes in Equity (Un-audited)**  
**For the Period ended June 30, 2013**

Taka'000

Half Year ended June 30, 2013								
	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Retained Earnings	Total	
<b>Balance as on January 01, 2013</b>	<b>3,046,390</b>	<b>5,269,475</b>	<b>1,689,637</b>	<b>294,951</b>	<b>1,406,528</b>	<b>6,701,181</b>	<b>18,408,162</b>	
Total Comprehensive Income	-	-	-	-	-	658,504	658,504	
Stock Dividend for 2012	456,959	-	-	-	-	(456,959)	-	
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(9,118)	9,118	-	
Adjustment for Deferred Tax on Revalued Assets	-	-	-	-	(41,221)	-	(41,221)	
<b>As on June 30, 2013</b>	<b>3,503,349</b>	<b>5,269,475</b>	<b>1,689,637</b>	<b>294,951</b>	<b>1,356,189</b>	<b>6,911,844</b>	<b>19,025,445</b>	
Number of Shares on June 30, 2013							350,334,907	
Net Asset Value (NAV) Per Share						Tk.	54.31	

Half Year ended June 30, 2012								
	Share Capital	Share Premium	Excess of Issue Price over Face Value of GDRs	Capital Reserve on Merger	Revaluation Surplus	Retained Earnings	Total	
<b>Balance as on January 01, 2012</b>	<b>2,517,678</b>	<b>5,269,475</b>	<b>1,689,637</b>	<b>294,951</b>	<b>1,466,603</b>	<b>5,889,785</b>	<b>17,128,129</b>	
Total Comprehensive Income	-	-	-	-	-	613,405	613,405	
Stock Dividend for 2011	528,712	-	-	-	-	(528,712)	-	
Adjustment for Depreciation on Revalued Assets	-	-	-	-	(10,360)	10,360	-	
Adjustment for Deferred Tax on Revalued Assets	-	-	-	-	(46,577)	-	(46,577)	
<b>As on June 30, 2012</b>	<b>3,046,390</b>	<b>5,269,475</b>	<b>1,689,637</b>	<b>294,951</b>	<b>1,409,666</b>	<b>5,984,838</b>	<b>17,694,957</b>	
Number of Shares on June 30, 2012							304,639,050	
Net Asset Value (NAV) Per Share						Tk.	58.08	

*Nazmul Hassan*

**Nazmul Hassan**  
 Managing Director

*Ali Nawaz*

**Ali Nawaz**  
 Chief Financial Officer

**Beximco Pharmaceuticals Limited**  
**Statement of Cash Flows (Un-audited)**  
**For the Half-year ended June 30, 2013**

Taka'000

	Half-Year ended June 30, 2013	Half-Year ended June 30, 2012
--	-------------------------------------	-------------------------------------

**Cash Flows from Operating Activities :**

Receipts from Customers and Others	4,917,071	4,300,864
Payments to Suppliers and Employees	(3,924,666)	(3,083,742)
<b>Cash Generated from Operations</b>	<b>992,405</b>	<b>1,217,122</b>
Interest Paid	(292,218)	(329,725)
Interest Received	248,664	204,036
Income Tax Paid	(115,816)	(88,647)
<b>Net Cash Generated from Operating Activities</b>	<b>833,035</b>	<b>1,002,786</b>

**Cash Flows from Investing Activities :**

Acquisition of Property, Plant and Equipment	(212,249)	(704,325)
Intangible Assets	(21,571)	(21,207)
Disposal of Property, Plant and Equipment	60	4,480
Short Term Investment	(110,820)	(353,195)
<b>Net Cash Used in Investing Activities</b>	<b>(344,580)</b>	<b>(1,074,247)</b>

**Cash Flows from Financing Activities :**

Net Increase / (Decrease) in Long Term Borrowings	(83,164)	(54,862)
Net Increase / (Decrease) in Short Term Borrowings	(359,646)	119,294
Ordinary Share Dividend	(22)	(132)
<b>Net Cash Generated from Financing Activities</b>	<b>(442,832)</b>	<b>64,300</b>
<b>Increase / (Decrease) in Cash and Cash Equivalents</b>	<b>45,623</b>	<b>(7,161)</b>
Cash and Cash Equivalents at Beginning of Period	552,979	518,768
<b>Cash and Cash Equivalents at End of Period</b>	<b>598,602</b>	<b>511,607</b>
<b>Net Operating Cash Flow Per Share</b>	<b>Tk. 2.38</b>	<b>3.29</b>

Number of Shares used to compute Net Operating Cash Flow Per Share	350,334,907	304,639,050
--	-------------	-------------

*Nazmul Hassan*

**Nazmul Hassan**  
Managing Director

*Ali Nawaz*

**Ali Nawaz**  
Chief Financial Officer

**Beximco Pharmaceuticals Limited**  
**Selected Notes to the Financial Statements (Un-audited)**  
**For the Period ended June 30, 2013**

**1. Reporting Entity**

Beximco Pharmaceuticals Limited (BPL/the Company) is a public company incorporated in Bangladesh in 1976. It commenced its manufacturing operation in 1980. The company is listed on Dhaka and Chittagong Stock Exchanges of Bangladesh and AIM of London Stock Exchange. The company is engaged in manufacturing and marketing of Pharmaceuticals Finished Formulation Products, Active Pharmaceutical Ingredients (APIs) and life saving Intravenous Fluids which it sells in the local as well as international markets. The registered office of the company is located at House No. 17, Road No. 2, Dhanmondi R/A, Dhaka. The Industrial units are located at Tongi and Kaliakoir of Gazipur District - vicinities close to the capital city Dhaka.

**2. Basis of Preparation of Financial Statements**

These interim financial statements should be read in conjunction with the Financial Statements for the year ended December 31, 2012 (hereafter referred to as the "Annual Financial Statements"), as they provide an update to previously reported information.

The accounting policies used are consistent with those used in the Annual Financial Statements. The financial statements have been prepared in accordance with the International Financial Reporting Standards (IFRSs). The presentation of the Interim Financial Statements is consistent with the Annual Financial Statements. Where necessary, the comparatives have been reclassified or extended to take into account any presentational changes made in the Annual Financial Statements. The preparation of the Interim Financial Statements requires management to make estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities at the date of the Interim Financial Statements. If in the future such estimates and assumptions, which are based on management's best judgment at the date of the Interim Financial Statements, deviate from the actual, the original estimates and assumptions will be modified as appropriate in the period in which the circumstances change.

	<b>As at June 30, 2013</b>	<b>As at December 31, 2012</b>
<b>3. Property, Plant &amp; Equipment</b>		
<b>Cost / Revaluation</b>		
Land	3,302,882	3,302,102
Building and Other Constructions	6,340,926	6,333,171
Plant & Machinery	7,454,110	7,393,576
Furniture & Fixture	164,502	157,600
Transport & Vehicle	459,542	458,377
Office Equipment	344,035	329,522
	<b>18,065,997</b>	<b>17,974,348</b>
Accumulated Depreciation	(4,402,592)	(4,114,781)
	<b>13,663,405</b>	<b>13,859,567</b>
Capital Work in Progress	2,462,740	2,342,291
<b>Carrying Value</b>	<b><u>16,126,145</u></b>	<b><u>16,201,858</u></b>

Taka'000

	As at June 30, 2013	As at December 31, 2012
<b>4. Inventories</b>		
Finished Goods	604,163	629,829
Raw and Packing Material (Including Work in Process and Transit)	1,892,928	1,737,244
Sample & Others	69,931	66,915
	<u><b>2,567,022</b></u>	<u><b>2,433,988</b></u>
<b>5. Loans, Advances and Deposits</b>		
Clearing & Forwarding	31,635	19,351
VAT	207,474	215,793
Security Deposit and Earnest Money	20,513	23,151
Capital Expenditure / Project Expenses	54,725	54,725
	119,150	63,699
Advance against Salary	60,269	64,266
Motor Cycle	118,206	132,315
Raw & Packing Material	350,813	330,283
Overseas Liaison Office	19,444	17,420
Others	60,584	44,273
	<u><b>1,042,813</b></u>	<u><b>965,276</b></u>
<b>6. Cash and Cash Equivalents</b>		
(a) Cash In Hand (Including Imprest Cash)	2,735	2,540
(b) Cash at Bank:		
i) Current & FC Account	106,986	85,035
ii) FDR Account	488,881	465,404
	<u><b>598,602</b></u>	<u><b>552,979</b></u>
<b>7. Long Term Borrowings</b>		
<b>A. Net off Current Maturity (Secured)</b>		
Project Loan	1,197,123	1,336,417
Obligation Under Finance leases	87,039	133,205
	<u><b>1,284,162</b></u>	<u><b>1,469,622</b></u>
<b>B. Current Maturity</b>		
Project Loan	674,677	568,589
Interest and PAD Block	-	3,792
Obligation Under Finance leases	92,332	92,332
	<u><b>767,009</b></u>	<u><b>664,713</b></u>



Taka'000


	Half Year ended June 30, 2013	Half Year ended June 30, 2012
<b>8. Cost of Goods Sold</b>		
Materials	1,987,741	1,745,854
Factory Overhead	480,474	361,255
Depreciation	260,551	260,434
	<b><u>2,728,766</u></b>	<b><u>2,367,543</u></b>
<b>9. Administrative Expenses</b>		
Salary & Allowances	81,937	68,214
Repairs & Maintenance	15,142	10,267
Travelling & Conveyance	8,546	8,425
AGM, Company Secretarial Expenses and Regulatory Fees	25,295	24,409
Depreciation	10,077	10,072
Other Expenses	55,167	29,495
	<b><u>196,164</u></b>	<b><u>150,882</u></b>
<b>10. Selling, Marketing and Distribution Expenses</b>		
Salary & Allowances	316,063	254,680
Travelling & Conveyance	132,043	112,038
Market Research & New Products	19,036	18,624
Sample, Literature & Promotional Expenses	288,885	235,531
Delivery Expense	146,901	116,679
Depreciation and Amortization	24,338	23,380
Other Expenses	66,065	54,486
	<b><u>993,331</u></b>	<b><u>815,418</u></b>

**11. Dividend for 2012**

The Shareholders of the company has approved 15% stock dividend for the year 2012 in the annual general meeting held on June 29, 2013. The company consistently follows the policy of recognising proposed dividend after its approval by the shareholders in the annual general meeting. Hence, the dividend for 2012 has been accounted for in this interim financial statements. EPS has been computed taking into account the additional number of shares issued.



**Nazmul Hassan**  
Managing Director



**Ali Nawaz**  
Chief Financial Officer

# Corporate Information

## **Operational Headquarters**

19 Dhanmondi R/A, Road # 7  
Dhaka 1205, Bangladesh  
Phone : +880-2-8619151, +880-2-8619091  
Fax : +880-2-8613888  
E-mail : info@bpl.net  
Website : www.beximcopharma.com

## **Corporate Headquarters**

17 Dhanmondi R/A, Road # 2  
Dhaka 1205, Bangladesh  
Phone : +880-2-8611891  
Fax : +880-2-8613470  
E-mail : beximchq@bol-online.com

## **Factory**

**Tongi Unit**  
126 Kathaldia, Tongi, Gazipur  
Bangladesh

**Kaliakoir Unit**  
Plot No. 1070/1083, Mouchak  
Kaliakoir, Gazipur  
Bangladesh

## **Stock Exchange Listing**

Dhaka Stock Exchange Ltd.  
Chittagong Stock Exchange Ltd.  
AIM of London Stock Exchange plc (GDRs)

## **Public Relations**

IMPACT PR  
Apartment # A-1, House # 17,  
Road # 4, Gulshan-1,  
Dhaka-1212, Bangladesh

FTI Consulting Group Limited  
Holborn Gate, 26 Southampton Buildings  
London WC2A 1PB, UK

## **Legal Advisor**

Rafique-ul Huq  
Barrister-at-Law  
47/1 Purana Paltan  
Dhaka-1000, Bangladesh

## **Auditors**

M. J. Abedin & Co.  
Chartered Accountants  
National Plaza (3rd Floor)  
109, Bir Uttam C. R. Datta Road  
Dhaka-1205, Bangladesh

## **Banker**

Janata Bank Ltd.  
Local office  
1 Dilkusha C/A  
Dhaka-1000, Bangladesh

## **For GDRs**

### **Nominated Advisor**

Libertas Capital Corporate Finance Limited  
21 Wilson Street  
London EC2M 2SN

### **Broker**

Daniel Stewart and Company PLC  
Becket House  
36, Old Jewry  
London EC 2R 8DD

### **Custodian**

HSBC  
Anchor Tower, 1/1-B, Sonargaon Road  
Dhaka-1205, Bangladesh

### **Depository Bank**

The Bank of New York Mellon  
101 Barclay Street  
New York, NY 10286



**BEXIMCO PHARMACEUTICALS LTD.**



*Winner*



Therapeutic Goods Administration



**AGES**  
Österreichische Agentur für Gesundheit  
und Ernährungssicherheit GmbH

*Certified*